Long‐term cost‐effectiveness of IDeglira versus basal‐bolus insulin as intensification therapies for people with type 2 diabetes inadequately controlled on basal insulin in Spain: projections based on the Dual VII trial
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.